Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease. / Nielsen, O H; Langholz, E; Hendel, J; Brynskov, J.
I: Digestive Diseases and Sciences, Bind 39, Nr. 9, 09.1994, s. 1918-23.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease
AU - Nielsen, O H
AU - Langholz, E
AU - Hendel, J
AU - Brynskov, J
PY - 1994/9
Y1 - 1994/9
N2 - Intercellular adhesion molecule (ICAM)-1 promotes the initial interaction between macrophages and T cells during immune activation. We have measured serum levels of soluble ICAM-1 (sICAM-1) by ELISA in 27 patients with ulcerative colitis (UC), 31 with Crohn's disease (CD), and 29 healthy subjects. The median sICAM-1 serum concentration was significantly increased in inflammatory bowel disease (IBD) patients (355 ng/ml, range 195-855) compared to controls (245 ng/ml, 155-580) (P = 0.001). Variance analysis for trend showed that sICAM-1 levels were significantly higher in patients with active CD and UC, compared to those with inactive disease and controls (P = 0.00002). The concentration of sICAM-1 was higher in CD patients (365 ng/ml 230-470) compared to UC (300 ng/ml 195-855) (P = 0.01). Furthermore, weak but significant correlations were found between serum levels of sICAM-1 and: soluble IL-2 receptors, orosomucoid, and C-reactive protein. It is suggested that increased circulating sICAM-1 levels may reflect increased adhesiveness and signal transmission across cells, probably as a result of shedding of the parent molecule during local cellular immunoresponses in vivo.
AB - Intercellular adhesion molecule (ICAM)-1 promotes the initial interaction between macrophages and T cells during immune activation. We have measured serum levels of soluble ICAM-1 (sICAM-1) by ELISA in 27 patients with ulcerative colitis (UC), 31 with Crohn's disease (CD), and 29 healthy subjects. The median sICAM-1 serum concentration was significantly increased in inflammatory bowel disease (IBD) patients (355 ng/ml, range 195-855) compared to controls (245 ng/ml, 155-580) (P = 0.001). Variance analysis for trend showed that sICAM-1 levels were significantly higher in patients with active CD and UC, compared to those with inactive disease and controls (P = 0.00002). The concentration of sICAM-1 was higher in CD patients (365 ng/ml 230-470) compared to UC (300 ng/ml 195-855) (P = 0.01). Furthermore, weak but significant correlations were found between serum levels of sICAM-1 and: soluble IL-2 receptors, orosomucoid, and C-reactive protein. It is suggested that increased circulating sICAM-1 levels may reflect increased adhesiveness and signal transmission across cells, probably as a result of shedding of the parent molecule during local cellular immunoresponses in vivo.
KW - Acute-Phase Proteins/analysis
KW - Adolescent
KW - Adult
KW - Aged
KW - Biomarkers/blood
KW - Cell Adhesion Molecules/blood
KW - Colitis, Ulcerative/immunology
KW - Crohn Disease/immunology
KW - Enzyme-Linked Immunosorbent Assay
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Receptors, Interleukin-2/analysis
M3 - Journal article
C2 - 7521822
VL - 39
SP - 1918
EP - 1923
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
SN - 0163-2116
IS - 9
ER -
ID: 218727365